Analyst firms · BofA Securities · CADL
BofA Securities CADL price target and rating history
Candel Therapeutics Inc. (CADL) · Health Care
BofA Securities rates Candel Therapeutics Inc. (CADL) Buy with a $18 price target, as of its latest action on Sep 21, 2026. It has published 3 rating actions on CADL since February 2025, including 1 upgrade and 1 downgrade. Across 3 firms with a CADL price target in the last 12 months, the median target is $22. BofA Securities's $18 is 18% below that.
- Current rating
- Buy
- Price target
- $18
- Median target, all firms
- $22
- Actions on CADL
- 3
BofA Securities price target on CADL
Every BofA Securities rating on CADL
- Sep 21, 2026
- Sep 3, 2025
- Feb 7, 2025
How other firms rate CADL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Jefferies | Buy | $25 | Oct 22, 2026 |
| BofA Securities | Buy | $18 | Sep 21, 2026 |
| Stifel | Buy | $22 | Jul 13, 2026 |
| Cantor Fitzgerald | Overweight | Apr 20, 2026 |
Questions about BofA Securities and CADL
- What is BofA Securities's price target for CADL?
- BofA Securities's latest stated price target for Candel Therapeutics Inc. (CADL) is $18, from its action on Sep 21, 2026.
- What is BofA Securities's rating on CADL?
- BofA Securities rates CADL Buy, a bullish rating, as of Sep 21, 2026.
- When did BofA Securities last change its view on CADL?
- On Sep 21, 2026, BofA Securities upgrades to Buy from Neutral, price target $18.
- How does BofA Securities's CADL target compare with other analysts?
- Across 3 firms with a CADL price target in the last 12 months, the median target is $22. BofA Securities's $18 is 18% below that.
All BofA Securities ratingsCADL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.